Kazia Therapeutics is making good progress with its two pipeline assets, paxalisib and EVT801, with the latter having cleared third dose level and is recruiting well.
The company also notes the GBM AGILE pivotal study has opened in France, the fourth country to start recruitment to the paxalisib arm.
Importantly, the Phase I study of paxalisib in combination with radiotherapy for the treatment of brain metastases at Memorial Sloan Kettering Cancer Center has been accepted for presentation at an upcoming academic conference in Q3 CY2022.
Kazia CEO Dr James Garner said of the latest developments, “Despite a challenging first half equity market for biotech companies, Kazia has continued to make good progress.
"The GBM AGILE pivotal study is progressing well and appears on track for data in 2H CY2023, as anticipated.
"We have been pleased in the first half to see new data presented and milestones delivered from several projects, and we expect that pace to continue and increase during the second half.”
The company has also highlighted its ATM financing facility, which has realised gross proceeds of US$2,956,036 for the period ending June 2022, at an average price of $6.08 (approximately A 0.88 per share).
Read more here.